Communiqués de presse
Archives
Novagali Pharma receives positive Scientific Advice from the European Medicines Agency for the Phase III clinical trial of Cyclokat® for the treatment of Dry Eye Disease
2011/01/05
Novagali Pharma Novagali Pharma (NYSE Euronext Paris: FR0010915553), a pharmaceutical company that develops innovative ophthalmic products, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase III clinical trial of Cyclokat®, its proprietary cationic emulsion of Ciclosporin, for the treatment of Dry Eye Disease (DED).
In order to receive
Genopole® press releases®,
please provide your coordinates
to Press Service
